Aggressive competition for the generic drugs arm of Merck of Germany pushed offers beyond €4bn ($5.5bn) at the close of a revised round of bids yesterday.
Four rivals - Actavis of Iceland, Teva of Israel, Mylan of the US and a joint private equity offer from Apax Partners and Bain Capital - all stayed in the auction after completing due diligence in recent weeks.
FT
Insider's money is still on Teva - but only a small bet!
No comments:
Post a Comment